Aardvark Therapeutics, Inc. Common Stock cash flow to debt ratio of -12.28K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aardvark Therapeutics, Inc. Common Stock's free cash flow has decreased 198.24% from $-18.20M last year to $-54.27M, signaling decreasing performance

Aardvark Therapeutics, Inc. Common Stock's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Aardvark Therapeutics, Inc. Common Stock's debt has increased relative to shareholder equity from -0.01 last year to 0.00 today, signaling weakened financials

Aardvark Therapeutics, Inc. Common Stock has a net cash position, so leverage is healthy.

Aardvark Therapeutics, Inc. Common Stock earns at least as much interest as it pays. Interest obligations are fully covered.

Aardvark Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Aardvark Therapeutics, Inc. Common Stock's short-term assets of $111.89M exceed its short-term liabilities of $10.55M

Aardvark Therapeutics, Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aardvark Therapeutics, Inc. Common Stock's return on equity of -61.71%, is lower than 15.00%, indicating bad performance

Aardvark Therapeutics, Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aardvark Therapeutics, Inc. Common Stock has insufficient public price history to evaluate earnings stability.

Aardvark Therapeutics, Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Aardvark Therapeutics, Inc. Common Stock has negative free cash flow, indicating cash burn

Aardvark Therapeutics, Inc. Common Stock's yearly earnings has decreased 179.73% since last year from $-20.59M to $-57.59M, signaling decreasing performance

Aardvark Therapeutics, Inc. Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -85.57% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aardvark Therapeutics, Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.

Aardvark Therapeutics, Inc. Common Stock has insufficient public price history to evaluate revenue consistency.

Aardvark Therapeutics, Inc. Common Stock has insufficient public price history to evaluate ROE consistency.

Aardvark Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Aardvark Therapeutics, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aardvark Therapeutics, Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aardvark Therapeutics, Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aardvark Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Aardvark Therapeutics, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aardvark Therapeutics, Inc. Common Stock has a price-to-book ratio of 1.90x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aardvark Therapeutics, Inc. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue